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Abstract 
Antihuman T-lymphocyte immunoglobulin is still much debated in the setting of transplant from an 
HLA matched related donor. Acute and chronic graft-versus-host disease are the main cause of 
morbidity and mortality after allogeneic hematopoietic stem cell in patients with myelofibrosis. The 
aim of this study was to evaluate the effect of antihuman T-lymphocyte immunoglobulin in a large 
cohort of patients with myelofibrosis. 287 patients were included in the study. Cumulative incidence 
of grade 2-4 acute graft-versus-host disease was 26% and 41% with or without antihuman T-
lymphocyte immunoglobulin. Chronic graft-versus-host disease incidence was 52% and 55%. Non-
adjusted overall Survival, Disease Free Survival and non-relapse mortality were 55% vs 53%, 49% vs 
45%, and 32% vs 31%, respectively with or without antihuman T-lymphocyte immunoglobulin. An 
adjusted model confirmed that acute graft-versus-host disease risk was lower following antihuman T-
lymphocyte immunoglobulin (Hazard ratio : 0.54, p=0.010) whilst it did not decrease the risk of 
chronic graft-versus-host disease. Hazard ratio for overall survival and non-relapse mortality were 
0.66 and 0.64, with p-value at 0.05 and 0.09, respectively. Antihuman T-lymphocyte immunoglobulin 
did not influence disease-free survival, graft-versus-host disease and relapse free survival and relapse 
risk. In conclusion, in the setting of matched related transplantation in myelofibrosis patients, this 
study demonstrates that antihuman T-lymphocyte immunoglobulin decreases acute graft-versus-
host disease risk without increasing relapse risk. 
 
Article summary 
• This study from EBMT registry explores the role of ATG in myelofibrosis patients who 
underwent an HLA-matched related donor transplantation 
• Acute GVHD was decreased with ATG but not chronic GVHD and DFS was similar with or 
without ATG  
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Introduction 
Primary myelofibrosis (MF) or MF secondary to Polycythemia Vera or Essential Thrombocythemia are 
myeloproliferative neoplasms characterized by progressive fibrosis of the marrow and myeloid 
metaplasia in the spleen and the liver. Disease severity can be assessed by a number of different 
prognostic scoring systems, able to predict survival without treatment in patients with both primary 
or secondary MF 
1–5
. Usual risk factors taken into account within these scores are disease-related 
symptoms, the degree of cytopenia or hyperleucocytosis, peripheral or marrow blast excess and age. 
Moreover, cytogenetics and somatic mutations provide additional prognostication power to these 
scoring tools
3,6–9
. According to the number of risk factors, median expected survival from diagnosis 
can range from more than 10 years to less than 18 months. Allogeneic hematopoietic stem cell 
transplantation (HSCT) remains the only curative treatment in patients with MF. One registry based 
study demonstrated that patients with Dynamic International Prognostic Scoring System (DIPSS) 
intermediate-2 or high risk disease have an advantage in overall survival (OS) following 
transplantation strategies and international expert consensus guidelines are in favour of transplant in 
these patients 
10,11
. Cumulatively, overall survival (OS) after HSCT can range between 40 and 65% 
according to risk factors related to disease, patient and type of donor
12–18
. Results have been 
considered better with transplant from a HLA-matched sibling donor than an unrelated donor. 
However, acute and chronic GVHD remain frequent causes of death in patients with MF undergoing 
HSCT, often contributing to a relatively high transplant-related mortality of around 30%
12–18
. The 
optimal conditioning regimen and GVHD prophylaxis approach in these patients remains unknown. 
Two prospective studies of HSCT in MF, in which the conditioning regimen and GVHD prophylaxis 
strategies were homogeneous, can be detailed to compare GVHD rates and outcomes. In 2009, 
Kröger et al reported on 103 MF patients conditioned by fludarabine, busulfan and antihuman T-
lymphocyte immune Globulin Grafalon® at 30mg/kg using a matched related donor and at 60 mg/kg 
for an unrelated donor, combined with cyclosporine and short course of methotrexate. With this 
regimen including in vivo T-cell depletion approach, the acute grade 2-4 GVHD rate was relatively low 
(27%) and chronic GVHD incidence was 49%. Relapse incidences were 32% in the setting of a 
matched related donor and 20% with an unrelated donor (not significantly different). Rondelli et al, 
subsequently reported on a second prospective trial for MF HSCT using a fludarabine and melphalan 
platform in patients transplanted from a matched related donor, with the addition of 
Thymoglobulin® in patients with an unrelated donor
17
. Acute GVHD rates were significant at 38% and 
41%, in the sibling group and unrelated group respectively. Chronic GVHD rates did not differ 
significantly between the sibling (36%) and unrelated donor (38%) setting. Of particular note, 
4 
 
mortality was dramatically higher (68%) in the group of patients who underwent unrelated donor 
HSCT but the effect of ATG on this higher mortality risk remains undetermined. Collectively, from 
these 2 studies, we can see that in the matched related setting, it is not obvious to conclude ATG is 
beneficial. Recently, a randomized trial has shown that ATG prevents chronic GVHD in the setting of 
HLA-matched sibling donor for acute lymphoid leukemia or acute myeloid leukemia following myelo-
ablative conditioning regimens (MAC)
19
. Indeed, while acute GVHD was non-significantly lowered, the 
cumulative incidence of chronic GVHD dropped from 69% without ATG to 32% with Grafalon® 
without increasing the relapse risk. In this large EBMT cohort, we aimed to determine the effect of 
ATG in the setting of HSCT for MF using a HLA-matched sibling donor, which is of particular 
importance as data remains scarce given the rarity of the disease. 
 
Methods 
Consecutive patients transplanted from a matched sibling donor without ex vivo graft manipulation 
between 2007 and 2015 for MF and registered in the EBMT registry were included in this study. 
Patients who received post transplant cylocphosphamide, alemtuzumab and those without sufficient 
information regarding blood cell counts prior to transplantation were excluded. A total of 287 
patients were selected for the final analysis, amongst whom a total of 135 received in vivo T-cell 
depletion while 152 did not. 
DIPPS was calculated according to the original definition
1
. Some patients had missing data for 
peripheral blast count at transplant, in these cases, the blast count was taken at diagnosis. General 
symptoms were either weight loss or sweat (only 2 patients had fever), 50 patients had missing data 
for constitutional symptoms. Because the brand of drug used for T-cell depletion was not available in 
the registry, a stepwise hypothetical strategy was formulated to identify patients who received 
thymoglobulin® and those who had received grafalon®: ATG dosages at 10 mg/kg or lower were 
considered as thymoglobulin® whereas dosages at 20 mg/kg or higher were considered as grafalon® 
based on usual doses in each brand. This was also checked by country where the HSCT occurred, as 
some countries used only grafalon®, others used thymoglobulin and some both products.  
DFS was defined as survival without disease relapse or progression documented in the registry. 
GVHD relapse-free survival (GRFS) was defined as survival without disease relapse or progression, 
without grade 3-4 acute GVHD and without chronic extensive GVHD documented in the registry. 
Analysis of failure time data used Kaplan Meier estimates, log-rank tests and Cox modeling unless 
competing risks existed, whereby cumulative incidence curves, Gray’s test and cause-specific Cox 
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models were used, respectively
20
. In estimating cumulative incidence of chronic GvHD, patients were 
censored at the time of DLI, as previously reported. Based on frailty models 
21
, we tested whether 
there were center effect on each outcome.   
The study complied with regulatory requirements, the declaration of Helsinki and Good Practice 
standards. Independent review board approved the study. Patients gave written informed consent. 
Results 
Patients and transplant characteristics 
Main patient, disease and transplant characteristics are described in Table 1. Median age was 56.9 
years [IQR, 50.6- 61.5], ranging from 22.1 up to 75.5 years. There was a majority of male patients 
(68%). Patients without (n=152) or with ATG (n=135) had similar characteristics regarding age, 
gender, type of MF (primary or secondary) but differed for other characteristics including 
splenectomy before transplant (38% vs. 9%), DIPSS score (int-2 or high: 59% vs. 68%), conditioning 
regimen (Table 1) and source of stem cells (marrow 17% vs. 2%). More patients in the ATG-group 
received calcineurin inhibitors alone (26% vs. 7%).Concerning pre-transplant therapy, 5 patients in 
the non-ATG cohort and 14 in the ATG cohort received the JAK inhibitor ruxolitinib (Novartis 
Pharmaceuticals, Geneva, Switzerland). Regarding the brand of ATG used, in the ATG-group, 37 
patients received Grafalon®, 96 received Thymoglobuline® and the brand was undetermined for 2 
patients.  
 
Engraftment 
Six patients had primary graft rejection (3 in the ATG and 3 in the non-ATG cohort). Four of these 
patients received a second HSCT and 3 of them were alive and in remission at the time of last 
reported follow-up. Cumulative incidence of neutrophil engraftment at day 60 was 96.3% (95%CI, 
90.9-98.5) and 94.1% (95%CI, 88.7-96.9) without or with ATG (p=0.35). Cumulative incidence of 
platelet recovery was 68.4% (95%CI: 60.3-75.2) and 80.3% (95%CI: 72.3-86.1) without and with ATG 
(p=0.09) at 6 months. Twenty-four patients (14 ATG and 10 non-ATG) had a secondary rejection at a 
median time of 9 months following HSCT and all but one had disease progression. Half of them 
received a second HSCT, which failed to achieve a remission. 
 
Outcome  
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Median time to onset of acute GVHD was 36 days. Cumulative incidence of grade II-IV acute GVHD 
was significantly higher without ATG: 41.4% (95%CI: 33.1-49.5) versus 26.2% (95%CI: 18.7-34.3) 
(p=0.0067) whereas the incidence of grade III-IV GVHD was similar in both groups (Figure 1). Median 
time to develop chronic GVHD was 198 days. The incidence of chronic GVHD was high > 50% for both 
groups of patients (Figure 1) without any significant differences according to ATG. Rates of chronic 
extensive GVHD were also similar in both groups. Cumulative incidence of relapse was 24.4% (95%CI: 
16.5-33.1) after ATG and 18.6% (95%CI: 12.1-26.1) without ATG (p=0.083). Non-relapse mortality was 
32.5% (95%CI: 24.4-40.7) with ATG versus 31% (95%CI: 20.9-41.6) without ATG. During the follow-up 
period, a total of 65 non-ATG patients and 44 ATG-patients died. The primary cause of death was 
related to MF progression in 34% non-ATG and 29% in ATG –patients, respectively. The 5-year OS 
(54.7% vs. 52.8%), disease-free survival (DFS) (49% vs 44.7%), and GRFS (29.3% vs 23.6%) were not 
significantly different on univariate analysis (Table 2) 
 
Effect of ATG 
Due to disparities between ATG and non-ATG group, univariate analysis gave no clue on ATG effect. A 
multiple variable model was generated to analyse the potential role of ATG on outcome 
(Supplementary table 1S). Age was the strongest variable significantly associated with OS, DFS, and 
NRM. Adjustment was made on age at transplant, Lille score, Karnofsky performance status score, 
splenectomy before transplant, intensity of conditioning regimen (RIC versus MAC) and source of 
stem cells (marrow versus peripheral blood). There was no centre effect for any outcome 
(Supplementary Table 2S). Table 3 shows the ATG effect for each outcome. Hazard ratio (HR) 
favoured ATG for OS (HR: 0.66, 95%CI: 0.43-1.00, p=0.05) and NRM (HR: 0.64, 95%CI: 0.39-1.07, 
p=0.09). Grade II to IV acute GVHD was significantly lower with ATG (HR: 0.54, 95%CI: 0.34-0.86, 
p=0.01) but this was not the case for either grade III-IV acute GVHD or chronic extensive GVHD. In 
this model, ATG had no significant impact on DFS, GRFS or relapse risk (see values in Table 3). Taken 
into account variables of the adjusted model, Figure 2 shows OS, DFS and GRFS. 
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Discussion 
While there is some evidence that in vivo ATG can be protective from acute and chronic GVHD 
occurrence, which may translate into a higher probability of GRFS in patients transplanted from an 
HLA matched related donor
19
, no specific data in patients with MF undergoing HSCT exists, due to its 
low patient numbers. In this retrospective study on behalf of the EBMT group, we analysed the 
impact of ATG in the largest documented cohort of patients with MF transplanted with a HLA-
matched related donor. Approximately half of patients received ATG which is higher than previously 
reported by the CIBMTR registry where only 11% of patients with a matched related donor received 
ATG
22
. ATG was less frequently used before 2010 (35% vs 51%). The majority of patients received a 
reduced intensity conditioning regimen and the preferred source of stem cells was peripheral blood. 
Our study demonstrated that acute GVHD was decreased following ATG but there was no impact on 
chronic GVHD. The lack of attenuated chronic GVHD risk is in contrast to the findings of the 
randomized trial comparing ATG versus non-ATG in the setting of matched related donor HSCT 
published recently by Kröger et al
19
. However, this study included patients with acute leukaemia who 
underwent MAC-platforms whereas our study included predominantly RIC regimens and focused 
only on MF. Of note, the rates of acute GVHD, even in patients who received ATG was relatively high 
in our cohort (26%) as compared to the prospective study cited above but not dissimilar from other 
studies including only MF patients
17,18
. Rates of chronic GVHD were significantly high even after ATG, 
indeed higher than previously reported in this disease setting. The question whether these MF-
patients are more susceptible to develop chronic GVHD is thus raised. We could postulate that these 
patients, who still have MF slowly resolving in the first months after transplantation have a pro-
inflammatory profile able to trigger GVHD. Indeed, MF is associated with elevated pro-inflammatory 
biomarkers  associated with both auto-immune disease or immune dysregulation 
23–26
 and it has 
been demonstrated that the marrow remains fibrotic at 3 months following HSCT in approximately 
half of patients
27
. Moreover, Hussain et al reported that even in cases of fibrosis resolution following 
HSCT, pro-inflammatory cytokines and tissue remodelling factors can remain elevated 
28
. In contrast, 
other cytokines remain downregulated following HSCT, such as the T-cell inhibitory receptor Tim-3 
(T-cell immunoglobulin and mucin-domain containing-3), which may play a role in GVHD control 
28,29
.  
While ATG clearly decreased the risk of acute GVHD, the adjusted model showed a trend towards 
improved OS in patients who received ATG (p=0.05). This higher risk of mortality may be explained by 
higher risk of acute GVHD even if the excess of mortality was not observed only in the first months 
post-transplant corresponding to GVHD. Treatment of GVHD and steroid refractory GVHD may 
contribute to mortality in patients who did not receive ATG. Of note, the definition of acute and 
chronic GVHD in the registry was still restricted to the chronological definition where GVHD occurring 
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the 100 first days was considered as acute GVHD but we had no data regarding late acute GVHD 
which is considered as chronic GVHD in this study. Indeed, the classification of acute and chronic 
GVHD was not done according to the latest National Institute of Health (NIH) consensus and indeed 
chronic GVHD may be overestimated because through inclusion of late acute GVHD
30
. Our analysis 
was based on registry data and GVHD was not recoded at posteriori according to NIH classification. 
The analysis of GRFS which captures both severe acute and severe chronic GVHD is an important 
endpoint in this setting, showing no difference with or without ATG. Of note, even if the risk of 
chronic GVHD is mostly influenced by a previous acute GVHD, other variables like 
immunosuppressive therapy management and cellular therapy may interfere in chronic GVHD risk. 
Finally, this is the first study which shows a trend to lower mortality using an ATG approach. Four 
prospective trials conducted in the unrelated setting and the aforementioned study in the matched 
sibling donor setting, have not reported a significant advantage in overall survival with ATG
19,31–33
. In 
contrast, one large prospective randomized trial has reported lower OS in patients receiving ATG in 
the setting of unrelated donor (RIC or MAC)
34
. It must be considered however that the dosing of ATG 
and their manufacturing process may also have an impact on outcome and differ in the various 
prospective trials. In the present EBMT study, we could identify patients who received 
thymoglobulin® or Grafalon® but due to small subgroup numbers, we could not make conclusions on 
individual products regarding their specific impact on outcome (data not shown). Absolute 
lymphocyte count may also contribute to ATG efficiency which could not be studied here through the 
registry
34
. We can just postulate that MF patients, who are usually naïve of intensive chemotherapy 
may arrive for transplantation with subnormal lymphocyte count, which can be targeted by ATG. 
Regarding relapse risk, it was not confirmed in the multivariable model that ATG increased the risk of 
relapse however relapse continued to occur late after HSCT without a real plateau highlighting the 
importance of long-term monitoring in MF patients who received an HSCT. 
In conclusion, this retrospective data analysis of MF patients undergoing HSCT registered in the 
EBMT registry confirms that in vivo ATG is able to protect against acute GVHD and possibly may 
decrease mortality rates. A prospective study is needed to confirm the role of ATG in MF patients 
transplanted from an HLA-matched related donor. 
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Table 1. Patient and transplant characteristics 
 No ATG ATG P value 
Total number  152 135  
Median age    ( IQR) 56 (50-61) 58 (51-62) 0.07 
Recipient gender 
   Male (%) 
   Female (%) 
 
100 (66) 
52 (34) 
 
94 (70) 
41 (30) 
0.53 
Median time from diagnosis to 
transplant in months (IQR) 
41 (15-120) 30 (9-84) 0.13 
Disease 
   Primary myelofibrosis (%) 
   Secondary myelofibrosis (%) 
   Transformation into AML (%) 
 
97 (64) 
44 (29) 
11 (7) 
 
83 (61) 
50 (37) 
3 (2) 
0.07 
Date of transplantation 
   Before 2010 
   2010 and after 
 
52 (34) 
100 (66) 
 
29 (21) 
106 (79) 
 
 
0.02 
Splenectomy before transplant (%) 42 (38) 12 (9) <0.0001 
Lille score 
   Low 
   Intermediate 
   High 
 
30 (20) 
78 (51) 
44 (29) 
 
31 (23) 
58 (43) 
46 (34) 
0.58 
DIPSS score 
   Low 
   Intermediate-1 
   Intermediate-2 
   High 
   Missing 
 
21 (18) 
27 (23) 
45 (39) 
23 (20) 
36 
 
6 (6) 
24 (25) 
32 (34) 
32 (34) 
41 
0.018 
Conditioning regimen 
  TBI-cyclophosphamide or fludarabine 
  Busulfan-cyclophosphamide 
  Fludarabine-busulfan*+/-other 
  Fludarabine-melphalan+/-other 
 
30 (20) 
18 (12) 
37 (24) 
62 (41) 
 
2 (1.5) 
2 (1.5) 
110 (81) 
14 (10) 
P< 0.0001 
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  FLAMSA 
  Fludarabine-thiotepa 
3 (2) 
2 (1) 
7 (5) 
0 
GVHD prophylaxis 
Calcineurin inhibitor alone 
Calcineurin inhibitor and methotrexate 
Calcineurin inhibitor and MMF 
Other  
Missing 
 
8 (5) 
63 (42) 
75 (49) 
4 (3) 
1 (0.6) 
 
39 (29) 
47 (35) 
46 (34) 
3 (2) 
0 
<0.0001 
Recipient CMV serostatus 
   Positive 
   Negative 
   Missing 
 
95 (63) 
57 (37) 
0 
 
82 (61) 
52 (39) 
1 
0.90 
Conditioning regimen 
   Reduced intensity 
   TBI based 
 
115 (76) 
39 (26) 
 
113 (84) 
3 (2) 
 
0.11 
<0.0001 
Source of stem cells 
   Marrow 
   Blood 
 
26 (17) 
126 (83) 
 
3 (2) 
132 (98) 
<0.0001 
Gender 
Male recipient / Female donor 
Male recipient / Male donor 
Female recipient / Female donor 
Female recipient / Male donor 
 
37 (24) 
63 (41) 
21 (14) 
31 (20) 
 
44 (32)  
50 (37) 
20 (15) 
21 (16) 
0.38 
Karnosfsky score, median [range]  
80% or more, n (%) 
 
90 [80-100] 
142/147 (96%) 
90 (80-100] 
116/124 (93%) 
 
0.27 
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Table 2. Outcome in patients with or without T-cell depletion (univariate) 
Outcomes: number of 
events 
No ATG 
(n=152) 
ATG 
(n=135) 
P value 
Neutrophil recovery 
60-day cum incidence 
143 
94.1% (88.7-96.9) 
130 
96.3% (90.9-98.5) 
Gray: p=0.35 
Platelet recovery 
180-day cum incidence 
104 
68.4% (60.3-75.2) 
108 
80.3% (72.3-86.1) 
Gray: p=0.09 
Grade II-IV acute GvHD 
4-mo cum incidence 
58 
41.4% (33.1-49.5) 
32 
26.2% (18.7-34.3) 
Gray: p=0.0067 
Grade III-IV a GVHD 
4-mo cum incidence 
18 
11.9% (7.3-17.6) 
20 
15.1% (9.6-21.7) 
Gray : p=0.47 
Chronic GVHD* 
5-year cum incidence 
75 
51.7% (43.1-59.6) 
62 
54.6% (44.5-63.7) 
Gray: p=0.47 
Extensive chronic GVHD * 
5-year cum incidence 
37 
25.8% (18.9-33.3) 
33 
28.3% (20.4-36.7) 
Gray: p=0.50 
Relapse  
5-year cum incidence 
24 
18.6% (12.1-26.1) 
29 
24.4% (16.5-33.1) 
Gray: p=0.083 
Non-relapse mortality 
5-year cum incidence 
45 
32.5% (24.4-40.7) 
31 
31.0% (20.9-41.6) 
Gray: p=0.56 
Death  
Median (95%CI) 
5-year OS 
65 
63.4 months (39.8-NA) 
54.7% (45.1-63.1) 
44 
64 months (44.7-NA) 
52.8% (42.1-66.3) 
Logrank p=0.43 
Cause of death 
Relapse/progression 
Other 
Unknown 
 
22 (34%) 
35 (54%) 
8 (12%) 
 
13 (29%) 
28 (64%) 
3 (7%) 
 
Fisher exact: p=0.52 
Relapse or death 
Median (95%CI) 
5-year DFS 
69 
59.5 months (29-NA) 
49.0% (40.6-59.0) 
60 
38.1 months (23.6-NA) 
44.7% (34.7-57.4) 
Logrank: p=0.46 
GVHD relapse death 
Median (95%CI) 
5-year GRFS 
95 
9.9 months (8.2-17.7) 
29.3% (22.0-38.9) 
86 
7.5 months (6.7-11.3) 
23.6% (15.8-35.2) 
Logrank: p=0.12 
*censored at DLI  
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Table 3. Adjusted effect of ATG for NRM, OS, DFS, GRFS, relapse, GVHD; adjustment on age at 
transplant, Lille score, Karnofsky performance status, splenectomy, conditioning regimen intensity 
and source of stem cells.  
 
 Hazard Ratio (96% CI) 
ATG versus none 
P-value 
OS 0.66 (0.43-1.00) 0.05 
Relapse 1.31 (0.71-2.42) 0.39 
NRM 0.64 (0.39-1.07) 0.09 
Grade 2-4 acute GVHD 0.54 (0.34-0.86) 0.01 
Grade 3-4 acute GVHD 1.11 (0.54-2.28) 0.77 
Chronic ext GVHD 1.17 (0.72-1.91) 0.52 
DFS 0.86 (0.59-1.27) 0.46 
GRFS 1.05 (0.76-1.46) 0.74 
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Figure legends.  
Figure 1. Acute and chronic GVHD. Top panels represents incidences of grade 3-4 and grade 3-4 
acute GVHD. Down panels represent incidences of chronic GVHD and chronic extensive GVHD. 
Figure 2. Adjusted survivals curves. From left to right, OS, DFS, GRFS in ATG-patients (red) and non-
ATG (black) with confidence interval (dotted line). Curves have been adjusted according to multiple 
Cox models. 
 
 


Supplemental tables 
Table 1S. Multivariable models 
 
Overall Survival 
 
Disease Free Survival 
 
Relapse 
 
Non relapse mortality 
 
GRFS 
 
 HR (95%CI) P-value HR (95%CI) P-value HR (95%CI) P-value HR (95%CI) P-value HR (95%CI) P-value 
ATG 0.66 (0.43-1.00) 0.05 0.86 (0.59-1.27) 0.46 1.31 (0.71-2.42) 0.39 0.64 (0.39-1.07) 0.09 1.05 (0.76-1.46) 0.75 
Age 1.04 (1.02-1.07) <0.0001 1.04 (1.01-1.06) 0.001 1.01 (0.98-1.04) 0.60 1.06 (1.03-1.09) <0.0001 1.03 (1.01-1.05) 0.002 
Lille score high 0.72 (0.45-1.16) 0.18 0.77 (0.50-1.20) 0.25 0.86 (0.44-1.70) 0.67 0.73 (0.41-1.30) 0.28 0.95 (0.65-1.39) 0.79 
Karnofsky score 0.76 (0.44-1.31) 0.32 0.65 (0.39-1.08) 0.19 0.41 (0.17-0.96) 0.04 0.89 (0.47-1.68) 0.72 0.87 (0.57-1.34) 0.54 
Splenectomy 0.98 (0.96-1.00) 0.07 0.99 (0.97-1.01) 0.21 0.98 (0.95-1.01) 0.24 0.99 (0.96-1.02) 0.51 0.99 (0.98-1.02) 0.87 
RIC 0.77 (0.45-1.31) 0.34 0.73 (0.44-1.22) 0.23 0.99 (0.46-2.12) 0.98 0.59 (0.29-1.18) 0.14 0.68 (0.45-1.04) 0.07 
PB* as source of SC  1.10 (0.65-1.87) 0.71 1.02 (0.62-1.65) 0.95 0.99 (0.46-2.13) 0.99 1.04 (0.55-1.94) 0.91 0.91 (0.61-1.36) 0.64 
 
Peripheral blood stem cells as source of stem cells. 
  
Table 1S. followed. 
 Chronic GVHD  
 HR (95%CI) P-value 
ATG 1.19 (0.73 to 1.93) 0.48 
Age 1.03 (1.00 to 1.06) 0.021 
Lille score high 0.96 (0.54 to 1.69) 0.88 
Karnofsky score 1.01 (0.98 to 1.04) 0.40 
Splenectomy 0.79 (0.41 to 1.50) 0.47 
RIC 0.93 (0.50 to 1.73) 0.82 
PB* as source of SC  1.42 (0.59 to 3.41) 0.44 
 
  
Table 2S. Center effect tested by frailty model 
Outcome Variance of random effect p-value 
Overall Survival 0.0959 0.17 
Disease Free Survival 0.106 0.15 
Relapse 0.118 0.28 
Non relapse mortality 0.248 0.11 
Acute GVHD, grade 3 or 4 <0.0001 0.94 
Chronic GVHD, severe 0.376 0.083 
Relapse GVHD Free Survival 0.028 0.30 
 
 
 
